Health In Tech Q3 Call: $32.7M Contracted Revenue, $156.4M Pipeline, FY26 Outlook ~$30M
HIT is trading near its 52-week low of $0.365 (10% above the low).
Summary
Health In Tech's Q3 call transcript confirms the $6.6 million revenue and $7.1 million net loss already reported, and adds $32.7 million of contracted revenue, a $156.4 million pipeline converting at 3%-7%, and a full-year 2026 outlook of roughly $30 million.
Key Events · Earnings and Guidance · HIT
-
Q3 Revenue Falls, Net Loss Swings
Q3 2026 revenue was $6.6 million versus $8.5 million a year ago; the net loss was $7.1 million, or $(0.11) per diluted share, including a $5.3 million provision for credit losses, versus net income of $0.5 million a year ago.
-
FY2026 Outlook Cut to ~$30M
Full-year 2026 revenue outlook was revised to approximately $30 million, modestly below 2025, citing delayed policy starts from a carrier transition.
-
Contracted Revenue and Pipeline Detail
Contracted but unrecognized revenue totaled $32.7 million for the first nine months of 2026, with $6.1 million due in Q4 and $2.2 million in 2027; pipeline revenue was $156.4 million as of October 30, 2026, with a 3%-7% expected conversion range worth $9.2 million to $10.7 million.
-
Cash Burn Improves, Balance Sheet Builds
Operating cash use narrowed to negative $1.0 million in Q3 from negative $3.3 million in Q1, a 68% reduction, and cash ended the quarter at $10.1 million versus $7.7 million at the end of 2025.
Analysis · HIT · Finance
The headline numbers were already out: Q3 revenue of $6.6 million versus $8.5 million a year ago, and a $7.1 million net loss driven by a $5.3 million credit-loss provision. What the transcript adds is the forward book—$32.7 million of contracted but unrecognized revenue, of which $6.1 million lands in Q4 and $2.2 million in 2027, plus a $156.4 million pipeline that management says converts at only 3% to 7%. That conversion range is the crux: even the high end yields roughly $10.7 million of revenue across the November-January policy window, which is why the full-year 2026 outlook sits at about $30 million, modestly below 2025. Against that, cash burn improved each quarter (negative $1.0 million in Q3 versus negative $3.3 million in Q1), and the $10.1 million cash balance is higher than the $7.7 million entering the year, so the runway question is less acute than the revenue trajectory. New CEO Sanjay Shrestha set 2027 milestones—HitRix MVP in Q1, HITChain in the second half, and a first Three-Year Rate Stabilization Program launch by end-2026—but explicitly declined to present a finalized 2027 plan until the Q4 call.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HIT was trading at $0.40 on NASDAQ in the Finance sector, with a market capitalization of approximately $25.8M. The 52-week trading range was $0.36 to $2.10. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.